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Current Status, Perspectives, and 
Future Directions of Multivessel 
Disease and Left Main Coronary 
Disease: Its Treatment by PCI or 
Surgery
Juan Mieres and Alfredo E. Rodríguez
Abstract
MVD has evolved from an era where it was mandatory to treat all lesions, even 
very thin vessels. With the advent of more realistic anatomical scores such as the 
ERACI score and the gradient measurements with the fractional flow of reserve 
(FFR) and instantaneous wave-free ratio (iwFR), a more conservative era has 
begun, which benefits the patient in the long-term follow-up. The treatment of 
the LMCA remains a challenging lesion because of the amount of irrigation. It 
can be divided the treatment of the LMCA with a low or high ERACI score, in the 
first group is where the PCI has gained in confidence and dedication in addition 
to knowledge and bifurcation techniques. The second group with high score can 
only be performed in centers with high PCI experience, since their alternative will 
always be surgical as the first choice. The revascularization in MVD with STEMI, the 
priority is the culprit vessel and then evaluate the underlying lesions, an invasive or 
with a functional test in the short term. The patient with DM is a singular patient, 
and its treatment should always be evaluated by a multidisciplinary team. We 
believe that patients with low ERACI score have the possibility of being treated with 
PCI, but patients with high score are surgical.
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1. Multivessel disease
1.1 Introduction
The revascularization of multivessel disease (MVD) has advanced considerably 
and has gone through periods where angioplasty with the advent of conventional 
stents (BMS) was competitive with surgery [1]. After the incorporation of drug-
eluting stents (DES) with the significant reduction of the revascularization of the 
treated vessel, it was thought that the percutaneous coronary intervention (PCI) 
would be superior to coronary artery bypass graph (CABG), with the advent of the 
SYNTAX trial [2], which also incorporated an anatomical score that revolution-
ized the way of stratifying the patients. Although this trial used stents that are not 
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currently marketed, called first-generation DES, later came trials with second-
generation stents that also failed to achieve the desired results [3]. An important 
element was the incorporation of the in vivo functional study of the lesion and its 
relation with the prognosis, which is the fractional flow of reserve (FFR) [4] and 
their instantaneous wave-free ratio (iwFR) [5], which gave a physiological view 
of the coronary disease and its treatment, although its use in stable patients such 
as the ORBITA trial [6] failed both by design and by results, since 85% of patients 
are finally revascularized, and the first randomized trial to assess functional lesion 
testing before CABG found patients who underwent FFR before CABG experienced 
similar rates of graft failure at 6 months as those who received angiography-guided 
by surgery [7]. We re-evaluated the SYNTAX score [8] first, and thus we generated 
an ERACI score [9] more in line with the modern treatment of severe and rational 
injuries at the time of complete revascularization, targeting medium-to-large 
caliber vessels, since only 70% lesions were included and vessel lesions larger than 
2 mm were included.
1.2 Main trails of PCI vs. CABG and meta-analysis in MVD
In our Argentine Randomized Trial of Coronary Angioplasty With Stenting vs. 
Coronary Bypass Surgery in Patients With Multivessel Disease (ERACI II) 1, where 
patients were randomized to PCI with BMS vs. CABG after 5 years of follow-up, 
there were no significant differences in the mortality of all causes, PCI 7.1% vs. 
CABG 11.5%, p = 0.182. In terms of nonfatal MI, the incidence was 6.2% in the 
CABG group and 2.8% in the PCI group (p = 0.128), where a significant difference 
was observed in the need for new revascularization, 7.2% in the CABG group and 
28.4% in the PCI group (p = 0.0002). MACCE was also larger in the PCI group than 
in the CABG, 24.5% vs. 34.7% (p = 0.019). A high rate of patients was asymptom-
atic without significant differences in both groups. The first randomized trial of 
patients with first-generation DES vs. CABG and with the creation of an anatomical 
score to assess severity divided the patients into three groups. This score was based 
on obstructions of at least 50% in vessels greater than 1.5 mm. Although this very 
basic score served to stratify patients, the SYNTAX study [2] compared CABG and 
PCI, followed by placement of paclitaxel-eluting stent in patients with MVD or 
left main disease (LMCA) or both. At 5 years of follow-up, it was observed that the 
MACCE between the two groups was significantly higher for the PCI group 37.3% 
than with the 26.9% CABG (p < 0.0001). The MI and the TVR was significantly 
higher in the PCI group than with surgery, but the mortality of all causes as well as 
the stroke was not significantly different between the two groups. When analyzed 
by groups, in the SYNTAX of low score ≤ 22, the MACCE was similar between both 
groups, but when analyzing intermediate scores 23–32 and high ≥33, it was signifi-
cantly higher with PCI commensurate with CABG. The randomized trial was subse-
quently carried out with the so-called second-generation DES. In the Randomized 
CABG and Everolimus-Eluting Stent EES Implantation in the Treatment of Patients 
with MVD, the BEST trial [3] was performed in 27 sites in East Asia and showed 
PCI with placement of EES. This study had as its primary end point the composite 
events of death, MI, and TVR. At 2 years of follow-up, it was observed that there 
were no significant differences with 11% events in the PCI group compared with 
7.9% in the CABG group (p = 0.32 for non-inferiority). In the long-term follow-up 
(4.6 years on average), the events of the primary end point occurred in 15.3% of 
patients in the PCI group and in 10.6% of those in the CABG group (p = 0.04). This 
is due to an excess of new interventions in the PCI group, since the TVR was signifi-
cantly higher in the PCI group (11.0% vs. 5.4%, p = 0.003). There were no signifi-
cant differences in mortality between the two groups, 6.6% in the PCI group and 
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5% in the CABG group (p = 0.30), as well as with the stroke (2.5 and 2.9%, respec-
tively; p = 0.72). The MI was higher in the PCI group than the CABG 4.3% vs. 1.6%, 
respectively p = 0.02. A recent meta-analysis of Brazilian origin [10] that includes 
randomized clinical trials (RCT) of multivessel disease performed a group analysis. 
They identified a total of 15 RCT that satisfied the requirements. The following 
results were obtained in the pooled data (n = 12,781). Thirty-day mortality and 
stroke were lower with PCI (1% vs. 1.7%, p = 0.01; and 0.6% vs. 1.7%, p < 0.0001). 
There was no difference in 1- and 2-year mortality (3.3% vs. 3.7%, p = 0.25; 6.3% 
vs. 6.0%, p = 0.5). Long-term mortality favored CABG (10.6% vs. 9.4%, p = 0.04), 
particularly in trials of DES era (10.1% vs. 8.5%, p = 0.01). In diabetics (DM) 
(n = 3274) long-term mortality favored CABG (13.7% vs. 10.3%, p < 0.0001). In six 
trials of LMCA (n = 4700), there was no difference in 30-day mortality (0.6% vs. 
1.1%, p = 0.15), 1-year mortality (3% vs. 3.7%, p = 0.18), and long-term mortality 
(8.1% vs. 8.1%) between PCI and CABG. The incidence of stroke was lower with 
PCI (0.3% vs. 1.5%, p < 0.001). DM and a high SYNTAX score were the subgroups 
that influenced more adversely the results of PCI (Table 1).
1.3 “Functional” complete or anatomic complete revascularization
The fractional flow reserve allows to measure the functional capacity of a ste-
nosis, and if it establishes a threshold of 0.80 (which is equivalent to a maximum 
intracoronary pressure drop of 20%), it determines a degree of ischemia. In fact, the 
use of this guide in patients with MVD showed that residual angiographic lesions 
that were functionally nonsignificant did not cause worse evolution [11] and thus 
indicated that they do not need treatment, giving a complete revascularization (CR) 
functional rather than anatomical, since the degree of injury is less important than its 
functional impact, as well as the magnitude of the territory that irrigates. However, 
the concept of “functional” CR with PCI was introduced many years ago even 
when FFR was not available. The ERACI I one of the first randomized clinical trials 
between PCI and CABG in MVD [12] showed similar outcomes in patients with com-
plete “functional” revascularization achieved with PCI and guided by noninvasive 
tests and in those with complete “anatomic” revascularization achieved with CABG.
1.4 ERACI risk score
The ERACI IV study [13] was a multicenter, observational, and prospective regis-
try with a second-generation DES in patients with MVD and LMCA. We built a score 
based on our experience in the treatment of patients with more realistic MVD; since 
our group led by Dr Rodriguez et al. aimed to treat more critical vessel lesions that 
irrigate a significant territory, based on this concept we created the ERACI score (ES) 
by modifying the SYNTAX score (SS), as well as the difference between the treated 
and residual lesions, their corresponding residual ES or residual SS. This reformu-
lated score included lesions greater than or equal to 70% in vessels larger than 2 mm. 
The analysis of the bifurcations and CTO was preserved as in the previous score. We 
included in a novel way the restenosis of the treated vessel that was cataloged as a 
severely calcified lesion. The rest of the variables were preserved as in the previous 
score [9] (Figure 1). The rationality of this revised score was previously published 
in our Journal of Interventional Cardiology of Argentina (RACI) 3 years ago [9]. With 
this new modality of scoring with the ES in the ERACI IV study, more than half of 
the patients had a low ES, and only 17% of the patients had a high score, in contrast 
to the SS that 34% of the patients were with a high score. The first analysis of this 
data is that with this score patients are re-categorized into a lower-risk group so they 
could be treated with either PCI or CABG. When we analyzed the residual untreated 
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Study Origin Date N MVD Characteristics UA EF Off-
pump
DM Outcome
AWESOME [76] USA 1995–2000 454 2v and 3v BMS, CABG 
previous
36 45 0 32 Survival rates for CABG and PCI were 79% versus 80% at 
36 months (log-rank test, p = 0.46)
ARTS [77, 78] International 1997–2000 1205 2v and 3v BMS, majority 2v 30 61 0 21 Event-free survival at 5 years: 58.3% for PCI vs. 78.2% for 
CABG (p < 0.0001)
ERACI II [1] Argentina 1196–1998 450 2v and 3v BMS, majority UA 92 ND 0 17 Freedom from MACE at 5 years was lower with PCI than 
with CABG (65.3% vs. 76.4%; p = 0.013)
SOS [79] Europe and 
Canada
1995–1999 988 2v and 3v BMS, majority 2v 33 Nd 3 15 At a median follow-up of 6 years, 53 patients (10.9%) 
died in the percutaneous coronary intervention group 
compared with 34 (6.8%) in the CABG group (HR, 1.66; 
95% CI, 1.08–2.55; p = 0.022)
MASS II [80] Brazil 1995–2000 408 2v and 3v BMS, clinical arm 36 65 0 30 The 10-year survival rates were 74.9% with CABG, 75.1% 
with PCI, and 69% with MT (p = 0.089)
LEMANS [29] Poland 2001–2004 105 LMCAD BMS and DES, DES 
if LM < 3.8
32 53 0 25 At 10 years, the mortality of PCI vs. CABG was (21.6% vs. 
30.2%; p = 0.41) and MACCE (51.1% vs. 64.4%; p = 0.28)
SYNTAX [2] Europe and 
USA
2005–2007 1800 LM and 3v DES Taxus 28 Nd 15 35 5-year MACCE in all: 37.3% for PCI vs. 26.9% for CABG 
(p < 0.001)
5-year MACCE in 3 VD: 37.5% for PCI vs. 24.2% for CABG 
(p < 0.001)
CARDia [74] UK 2002–2007 510 2v and 3v BMS and DES, only 
DBT
22 59 31 100 At 1 year of follow-up, the composite rate of death, MI, 
and stroke was 10.5% in the CABG group and 13.0% in the 
PCI group (HR, 1.25; 95% CI, 0.75–2.09; p = 0.39)
Boudriot et al. 
[81]
Germany 2003–2009 201 LMCAD DES (Sirolimus) ND ND 46 30 At 1 year of follow-up, the combined primary end point 
was 13.9% of patients after surgery, as opposed to 19.0% 
after PCI (p = 0.19 for non-inferiority)
PRECOMBAT 
[28]
Korea 2003–2009 600 LMCAD DES (Everolimus) 45 60 64 42 At 5 years, MACCE in PCI group and the CABG group 
(cumulative event rates of 17.5% and 14.3%, respectively; 
HR, 1.27; 95% CI, 0.84–1.90; p = 0.26)
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Study Origin Date N MVD Characteristics UA EF Off-
pump
DM Outcome
FREEDOM [67] International 2005–2010 1900 2v and 3v DES, only DBT 30 65 19 100 The primary outcome occurred more frequently in the PCI 
group (p = 0.005), with 5-year rates of 26.6% in the PCI 
group and 18.7% in the CABG group
Va-Cards [73] USA 2006–2010 198 2v and 3v DES, only DBT Nd Nd Nd 100 At 2 years, all-cause mortality was 5.0% for CABG and 
21% for PCI (HR, 0.30; 95% CI, 0.11–0.80); nonfatal 
myocardial infarction was 15% for CABG and 6.2% for 
PCI (HR, 3.32; 95% CI, 1.07–10.30)
BEST [3] Korea 2008–2013 880 2v and 3v DES (Everolimus) 42 59 64 45 MACE at 4.6 years: 15.3% for PCI vs. 10.6% for CABG 
(p = 0.04)
EXCEL [31] International 2010–2014 1905 LMCAD DES (Everolimus) 37 57 29 25 At 3 years, a primary end-point event had occurred in 
15.4% in the PCI group and in 14.7% in the CABG group 
(p = 0.02 for non-inferiority; HR, 1.00; 95% CI, 0.79–1.26; 
p = 0.98 for superiority)
NOBLE [30] Europe 2008–2015 982 LMCAD DES (Biolimus) 18 60 16 18 Kaplan-Meier 5-year MACCE was 28% for PCI and 18% 
for CABG (HR, 1·51; 95% CI, 1·13–2·00; p = 0·0044)
AWESOME, Angina With Extremely Severe Outcomes; ERACI II, Argentine Randomized Study: Coronary Angioplasty With Stenting Versus Coronary Bypass Surgery in Patients With Multivessel Disease; 
MASS II, Medicine, Angioplasty, or Surgery Study; ARTS, Arterial Revascularization Therapies Study; SOS, Stent or Surgery trial. SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery; 
CARDia: Coronary Artery Revascularization in Diabetes; Le Mans, Left Main Coronary Artery Stenting; FREEDOM, Future Revascularization Evaluation in Patients with Diabetes Mellitus; Va-Cards, 
Coronary Artery Revascularization in Diabetes in VA Hospitals; BEST, Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease; 
PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease; EXCEL, Coronary Artery 
Bypass Surgery for Effectiveness of Left Main Revascularization; NOBLE, Nordic-Baltic-British Left Main Revascularization Study [81]. DES, drug-eluting stents; BMS, bare-metal stent.
Modified from “Stent versus Coronary Artery Bypass Surgery in Multi-Vessel and Left Main Coronary Artery Disease: A Meta-Analysis of Randomized Trials with Subgroups Evaluation” (Pedro José Negreiros 
de Andrade, João Luiz de Alencar Araripe Falcão, Breno de Alencar Araripe Falcão, Hermano Alexandre Lima Rocha)
Table 1. 
Overview of the main trials of MVCAD and LMCAD.
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lesions between these two scores, we also found significant differences between these 
two groups of patients since with RSS it was 8.7 ± 5.9 vs. and with RES it was 3.5 ± 4.6, 
p = 0.003. In addition, reasonably incomplete revascularization was defined, defined 
by a residual of ≤5 (Table 2). If we take the RSS, only 35% of the patients reached 
this goal, but if we analyze it with the RES, they reached 80%, which suggests that 
most patients achieved a functional rather than an anatomical revascularization 
(Table 2). This could be corroborated in the long-term follow-up where these 
patients had a MACCE less than 10% at 3 years of follow-up. In addition, this score 
was validated in another trial of our group called the WALTZ registry [15]. A total 
of 201 real-life patients were included prospectively, in 11 centers in the Argentine 
Republic using the same criteria of ERACI IV. The study design, as well as the ratio-
nale, was previously published [14]. When we performed the analysis regarding the 
scores, we found a significant difference with respect to the baseline (SS 11.8 + 6.8 
vs. ES 7.8 + 5.3, p = 0.0016), and the same happened with the residual (RSS 5.4 + 5.6 
vs. RES 1.3 + 2.9, p < 0.001). The analysis that we carry out is that the presence of 
Figure 1. 
Modification of the SYNTAX score by ERACI score, with residual SYNTAX and ERACI scores and 
its implications. SYNTAX score = 28 points (red and white arrows). Hypothetically the patients need 
4 DES. Modified ERACI score, in the ERACI IV, the SYNTAX score (only the red arrows) was 16 
points = patient received 2 DES. The residual ERACI score was 3.5. If the patient was scored with the SYNTAX 
score, he would have had 17 residual SYNTAX score.
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neoatherosclerosis [16] that we believe is also present in the second- and third-gen-
eration stents is a growing concern, which is why this more rational strategy of the 
use of these devices can lead to better results long term. When we look closely at the 
results of the Syntax II study where iwFR was used, we can verify that the conserva-
tive strategy is beneficial [17]. When we compare the PCI group guided by the iwFR 
with the SYNTAX I in the PCI group, we find a decrease in MI and MACCE, similar 
to the SYNTAX I CABG group. SYNTAX II treated fewer lesions per patient than 
SYNTAX I (2.6 vs. 4, p < 0.001) and then implanted fewer stents per patient (3.8% 
vs. 5.2%, p < 0.001) despite the fact that the two groups of patients were scored simi-
larly, with SS (p = 0.16). These results are consistent with our ERACI IV trial. We also 
have to recognize that the FFR analysis has numerous limitations, among them it can 
be technically difficult in segments of diffuse disease, tandem lesions and bifurcation 
lesions. When performed in patients with severe aortic stenosis, the evaluation is 
more complex to analyze. Also you have to assume the cost of catheters that cannot 
be ignored. It is also important to mention that studies of CABG guided by FFR [18] 
have not achieved the expected results when compared when guided by angiography, 
and studies such as FAME 2 comparing optimal medical treatment vs. guided PCI 
have not observed reduction in MI or long-term mortality [19].
1.5 Guidelines
The evidence suggests that in MVD without DM and low anatomical complex-
ity, PCI and CABG achieve similar long-term outcomes with respect to survival 
and the composite of death, MI, and stroke, justifying a class I recommendation 
for PCI. Consistent results were also obtained for patients with MVD in the recent 
individual patient-level meta-analysis. Thus, the previous class III recommendation 
for PCI in MVD and intermediate-to-high complexity was maintained [20]. The 
intermediate and high SYNTAX scores are associated with better evolution with the 
CABG. Although this score is very limited and impractical for its application, its use 
for making decisions in patients with MVD is reasonable [21]. The ERACI score could 
be more rational for making decisions due to being more realistic and conservative [9].
1.6 Ongoing trials
The Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization 
Combined with Surgical Bypass and Percutaneous Coronary Intervention Using 
SYNTAX score ERACI score P value
Number of patients (n) 225 225
Low group 33.8% 54.8% < 0.001
Intermediate group 32.4% 27.9% = 0.35
High group 33.8% 17.2% <0.001
Baseline mean 27.7 ± 11.3 22 ± 11.02 =0.0004
Residual mean 8.7 ± 5.9 3.5 ± 4.6 =0.003
Residual ≤5 35% 80% <0.001
Residual <8 48% 93.5% =0.002
From “Lowering Risk Score Profile During PCI in Multiple Disease is Associated with Low Adverse Events: The 
ERACI Risk Score” (Alfredo E. Rodriguez, Carlos Fernandez-Pereira, Juan Mieres, Hernan Pavlovsky, Juan del Pozo, 
Alfredo M. Rodriguez-Granillo, David Antoniucci, On behalf of ERACI IV Investigators)
Table 2. 
Differences in baseline and residual risk scores: ERACI IV registry.
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Everolimus-Eluting Metallic Stents evaluates the efficacy of hybrid coronary revas-
cularization (HCR) combining CABG and PCI in the treatment of MVD. CABG is 
to be performed in the left anterior descending artery and the left circumflex artery 
using only arterial grafts, whereas PCI is to be conducted for the treatment of the 
right coronary artery with everolimus-eluting stents (EESs) [22]. The Comparison 
of One-stop Hybrid Revascularization vs. Off-pump Coronary Artery Bypass for the 
Treatment of Multi-vessel Disease combines minimally invasive direct CABG and PCI 
to be performed in the hybrid operating suite, an enhanced operating room equipped 
with radiographic capability [23].
1.7 Conclusions
In our long experience in the treatment of MVD for more than two decades 
and according to our score, we believe that the stratified treatment can be divided 
into two groups, patients with low and intermediate scores in whom the results of 
PCI are comparable with surgery. The other group of patients are those with high 
scores, we think that the current state-of-the-art CABG is the treatment of choice. 
However, with the increase in stent technology this difference can be reduced.
2. Left main coronary artery disease
2.1 Introduction
LMCA is a disease with significant morbidity and mortality, since it threatens a 
large myocardial territory. LMCA stenosis occurs in approximately 15% of patients 
with symptomatic ischemic heart disease [24]. The most common cause of LMCA 
disease is atherosclerosis, which is rarely focal and involves bifurcation in 80% of 
cases, which usually extends from the LMCA to the LAD [25]. In the beginning, the 
treatment of choice for this disease was the CABG [26]. However, after the intro-
duction of PCI, there was a growing interest in the treatment of the LMCA. Both 
European [20] and American [21] guidelines recommend CABG (class I) as the 
treatment of choice for LMCA in patients with low risk score. These recommen-
dations were based mainly on the results of the LMCA subgroup analysis of the 
SYNTAX trial (705 patients) that showed no differences in the MACCE between 
CABG and PCI in patients with LM disease [27]. Patients treated with PCI had 
a lower stroke but a higher revascularization rate than CABG. The results of the 
PRECOMBAT trial [28] compare PCI to CABG in the treatment of LMCA. The two 
groups did not differ significantly in MACCE. Ischemia-driven revascularization 
occurred more frequently in the PCI group than in the CABG group. In addition, the 
LE MANS trial [29] with a 10-year follow-up compared PCI and CABG in patients 
with LMCA with low or medium SYNTAX score. The primary end point was the left 
ventricular ejection fraction (LVEF) that was slightly higher in the PCI group than 
the CABG group. The introduction of new-generation DES with proven efficacy and 
safety prompted the design of two large randomized trials: the Nordic-Baltic-British 
Left Main Revascularization Study (NOBEL) [30] and the Evaluation of Xience ver-
sus Coronary artery bypass surgery for Effectiveness of Left main revascularization 
(EXCEL) trial [31]. It is important to note that, when an LMCA PCI is performed, 
there is a greater awareness of the need to achieve optimal procedural results by 
using the available technologies, including the most effective stents, intravascular 
evaluation of image, and physiology. And when one faces a real bifurcation with a 
Medina classification [32], it is necessary to use two stents. It would seem that the 
best technique is double kissing balloon with crush (DKC) [33].
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2.2 Main trials of the LMCA
LE MAS trial, [29] in this prospective, multicenter trial, randomly assigned 
105 patients with LMCA with low and medium complexity of coexisting coronary 
artery disease according to SYNTAX score to PCI with stenting (n = 52) or CABG 
(n = 53). DES were implanted in 35%, whereas arterial grafts to the left anterior 
descending artery were utilized in 81%. This study is very interesting because it 
offers a 10-year follow-up, which as a primary end point was the evaluation of the 
ejection fraction between PCI and CABG in the treatment of LMCA. Although 
there were no significant differences, there was a tendency in favor of PCI 
(54.9 ± 8.3% vs. 49.8 ± 10.3%, p = 0.07). Regarding mortality, MI, and TVR, there 
were no statistical differences between the two groups, although there was also a 
trend of greater MACCE-free survival in the PCI group (34.7% vs. 22.1%, p = 0.06; 
reason risk, 1.71; 95% confidence interval (CI), 0.97–2.99). The Nordic-Baltic-
British Left Main Revascularization Study [30] is a prospective, randomized, 
open-label, non-inferiority trial done at 36 centers in Europe. Patients were ran-
domized to CABG or PCI. LMCA were visually assessed with diameter ≥ 50% or 
fractional flow reserve ≤0.80 in different segments of the left main coronary artery. 
SYNTAX score was calculated and all patients with low, medium, and high score 
were included. Patients were treated with the intention of achieving CR. Biolimus-
eluting stent was the recommended stent in this trial. Distal bifurcation lesions 
could be treated with various techniques preferably by the “culotte” technique. 
IVUS was strongly recommended pre- and post-stent deployment. In the CABG 
group, the left internal mammary artery was recommended for revascularization 
of the left anterior descending coronary artery, and for the other lesions, saphenous 
venous grafts, free arterial grafts, or the right internal mammary artery could be 
used. The primary end point was a MACCE. About 1184 patients were included in 
the analysis (592 patients in each group). The SYNTAX scores were similar between 
the two groups (22.4 in the PCI group and 22.3 in the CABG group). CABG was 
performed with the on-pump technique in 84% of patients, and 96% of patients 
underwent arterial grafting of the left anterior descending artery. Kaplan-Meier 
estimates of MACCE were significantly higher in PCI (28%) than in CABG (18%). 
The rate of MI and revascularization was significantly higher in PCI group than 
in CABG, but the overall mortality and stroke were not statistically significant. At 
30 days, the stroke rate in PCI group was significantly less than in the CABG group, 
but this difference was not seen at 1- and 5-year follow-up. The EXCEL trial [31] 
was a prospective randomized open-label, non-inferiority trial undertaken at 126 
centers in 17 countries around the world. Patients were randomized to receive either 
CABG or PCI. Patients who had stable and unstable angina were included in the 
study; however patient who were having MI were excluded. Patients were included 
if they had LMCA of 70% assessed visually or 50–70% determined by means of 
invasive or noninvasive methods. SYNTAX score was determined and patients who 
had score of higher than 33 were excluded. CR was the intention of treatment in 
both groups. A second-generation DES EES was used in this study. Distal bifurcat-
ing lesions were treated with a two-stent strategy using various techniques. CABG 
was performed both on- and off-pump, with the aim of CR for vessels with 50% 
stenosis. Arterial grafts were strongly recommended. The primary end point was 
MACCE at 3 years. The intention-to-treat (ITT) analysis was used in this trial. A 
total of 1905 patients underwent randomization, 948 were assigned to the PCI 
group and 957 to the CABG group. The SYNTAX score according to assessment at 
local sites was low (≤22) in 60.5% of the patients and intermediate (23–32) in 39.5% 
of the patients. Distal LMCA was present in 80.5% of the patients. IVUS imaging 
guidance was used in nearly 80% of the patients in the PCI group. There was no 
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difference between the two groups in respect to the primary composite end-point 
event of death, stroke, or myocardial infarction at 3 years (15.4% of the patients 
in the PCI group and in 14.7% of the patients in the CABG group). At 3 years, the 
composite end-point event of death, stroke, myocardial infarction, or ischemia-
driven revascularization had occurred in 23.1% of the patients in the PCI group and 
in 19.1% of the patients in the CABG group. Ischemia-driven revascularization dur-
ing follow-up was more frequent after PCI than after CABG (in 12.6% vs. 7.5% of 
the patients, p < 0.001). Stent thrombosis occurred in only 0.7% of patients within 
3 years after the procedure and was less common than symptomatic graft occlusion. 
In the Premier of Randomized comparison of Bypass surgery versus Angioplasty 
using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease 
(PRECOMBAT) [28] trial was a randomized study where 600 patients with LMCA 
went to PCI with a first-generation of DES or CABG. The primary end point was the 
combined events, MACCE, at 5 years of follow-up 17.5% were observed in the PCI 
and 14.3 % in the CABG group, p = 0.26. Regarding the mortality of all causes, MI 
or stroke, there were no significant differences. The TVR was more frequent with 
PCI than with CABG (11.4% vs. 5.5%, p = 0.012).
2.3 Analysis of the two principal trials
As we could see in these last two studies on PCI and CABG in the LMCA, we 
can see that the NOBLE [30] study included higher-risk patients and used a phar-
macological stent with biodegradable polymer. In addition to the fact that the most 
frequently used technique was “culotte” by recommendation, the use of IVUS was 
only 75% in post PCI patients, and only 55% of the kissing balloon was performed. 
In addition the use of the proximal optimization (POT) was not specified, and first-
generation stent was also used in 8% of patients. In the EXCEL study [31], a second-
generation stent was used in patients with low and intermediate SYNTAX scores, 
and the amount of IVUS used reached 77%. The use of POT was also not specified, 
no special bifurcation technique was recommended, and the use of kissing balloon 
was also not specified (Table 3).
2.4 Meta-analysis
The objective was to compare clinical results and safety during short- and 
long-term follow-up by conducting a meta-analysis of large pooled data from 
randomized controlled trials and updated observation. The primary outcome was 
MACCE, MI, stroke, all-cause mortality, and revascularization after at least 1 year 
of follow-up. A subgroup analysis was also performed with a follow-up of over 
5 years. A total of 29 studies with 21,832 patients (10,424 with PCI and 11,408 with 
CABG) were analyzed. At 1-year follow-up there was a significant difference in 
favor of the CABG in MACCE, TVR, and MI, but the stroke was significantly lower 
in the PCI group. In the 5-year group analysis, it showed similar results except that 
the MACCE showed no inferiority in the PCI group. This meta-analysis concludes 
that the PCI for the LMCA can be applied in carefully selected patients. The MI and 
the TVR remain worrying, although we must consider that most of these studies 
have used first-generation DES [34].
2.5 PCI strategy and technique
Angioplasty is a specialty where the practice generates a greater capacity to solve 
problems during the procedure. It has been seen that those operators who perform 
at least 15 PCI of LMCA per year in 3 consecutive years obtain better results [35]. 
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The PCI of the ostium and the middle third of the LMCA is technically easier if we 
analyze it by the ERACI score this doesn’t give more than 5 points, unlike the distal 
third that compromises ostium of the two coronaries and presents higher ERACI 
scores [36]. When one faces the distal third of the LMCA, there is a totally differ-
ent approach. Anyway there are different types of bifurcations, where we prefer to 
use the Medina classification [32]. To assess them, the provisional stent technique 
has become a technique with a lot of boom and has had good results compared to 
techniques with two stents [37]. The technique of the provisional stent has been 
used in up to two thirds of the branches of the LMCA. However, after two RCTs 
where the DKC was used as a technique, these tests presented better results than 
the culotte technique or the provisional stent for the treatment of bifurcations 
EXCEL NOBLE
Inclusion criteria - Unprotected left main coronary artery 
(ULMCA) disease or left main equivalent 
disease
- Clinical and anatomic eligibility for both 
PCI and CABG as agreed to by the local heart 
team
- Silent ischemia, stable angina, unstable 
angina, recent MI with normalization of 
CK-MB prior randomization
- In addition to randomized patients, it also 
includes universal registry
- Stable, unstable angina pectoris, 
or acute coronary syndrome
- Significant ULMCA with no more 
than three additional noncomplex 
PCI lesions
- Patient eligible to be treated by 
CABG
and by PCI
Main exclusion 
criteria
- Prior PCI of the left main at any time prior 
to randomization or prior PCI of any other 
(non-left main) coronary artery lesions 
within 1 year prior to randomization
- Prior CABG
- Need for any concomitant cardiac surgery
- Inability to receive dual antiplatelet therapy 
for at least 1 year
- Pregnancy or intention to become pregnant
- Life expectancy less than 3 years
- ST elevation infarction within 
24 h
- Patient is too high risk for CABG
- Expected survival less than 1 year
- Allergy to aspirin, clopidogrel, or 
ticlopidine
Angiographic 
exclusion criteria
SYNTAX score ≥ 33
- Visually estimated left main reference vessel 
diameter < 2.25 mm or > 4.25 mm (post-
dilatation up to 4.5 mm is allowed)
- CABG clearly better treatment 
option
(LMCA stenosis and > 3 or complex 
additional coronary lesions)
Primary end 
point
- Death, MI, and stroke - Death, stroke, non-procedural 
MI, and new revascularization 
(PCI or CABG)
Sample size 1.905 1200
Participating 
centers
131 36
Main results At 3 years, a primary end-point event had 
occurred in 15.4% of the patients in the PCI 
group and in 14.7% of the patients in the 
CABG group
At 5 years, primary end points 
occurred in 28% of the patients 
in PCI group and in 18% of the 
patients in the CABG group
Conclusion In patients with left main coronary artery 
disease and low or intermediate SYNTAX 
scores, PCI was non-inferior to CABG
CABG might be better than PCI 
for treatment of left main stem 
coronary artery disease
Modified from “NOBLE and EXCEL: The debate for excellence in dealing with left main stenosis” (Hamood Al Kindi, 
Amir Samaan, Hatem Hosny)
Table 3. 
Comparison of EXCEL and NOBLE trials.
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with Medina 1,1,1 or 0,1,1 [33, 38]. In both studies, a reduction in ischemic events 
was observed. The decision to use a bifurcation technique with one or two stents is 
basically in the exact evaluation of the compromise of the origin of the left coronary 
circumflex or the left coronary ramus in a trifurcation. The best way to assess these 
vessels is with the images of the IVUS or the optimal coherence tomography (OCT) 
[39]. When the provisional stent technique is used and a residual obstruction of 
around 50% is observed, the measurement with functional study with iwFR or 
FFR could be considered as a complement in the decision-making of its definitive 
treatment. The use of kissing balloon and POT has been invoked as optimizers for 
this complex carrefour. Also, the post-stent images or stents of both the IVUS and 
the OCT are important when making decisions, since these elements clearly inform 
two elements that are key such as uncovered dissections or stent not well positioned 
[40]. The technique used in the treatment of LMCA is extremely important, just as 
training in true bifurcation is also difficult. Patients with true bifurcation are those 
who have Medina 1,1,1 or 0,1,1 and should be treated with two stents and we believe 
that the technique of choice is DKC. Another important element is to only include 
patients with low and intermediate ERACI score [17] and leave patients with high 
scores for very selected centers and true contraindication or patients who really 
refuses surgery. The use of images in diagnosis, implantation, and postimplantation 
has become a mandatory strategy, including the use of IVUS and optimal coherence 
tomography [41]. An element that has been incorporated into the technical arsenal 
is the technique of proximal optimization. The proximal optimization technique 
is a key part of treating large bifurcation lesions and will optimize results of both 
single- and two-stent strategies. An appropriately sized balloon should be posi-
tioned and inflated just up to the carina. When performed well, the enhanced lesion 
scaffolding, reduced strut mal-apposition, and improved flow dynamics are likely 
to translate into improved clinical results [42].
2.6 Guidelines
The evidence is clear regarding patients with low scores, where treatment with 
both PCI and CABG is appropriate, where there is a class I recommendation. In 
patients with high scores, because the evidence is much lower because many of 
these patients have been excluded from RCTs, the recommendation for PCI is class 
III, since the benefit is clearly greater with CABG. In patients with intermediate 
scores, due to the lack of evidence in the long-term follow-up, the recommenda-
tion remains IIa [20, 43]. When one makes a global evaluation of the LMCA and 
addresses the guidelines, one must also take into consideration the different por-
tions of the LMCA such as the ostium, the middle third, and the distal third, since 
they have different implications, both in the technique and in the evolution of these 
patients, so they would probably have to be analyzed separately. Also the degree 
of angiographic stenosis has been changing and should not be left with the 50% 
obstruction that has been used universally, and perhaps it should be passed at least 
70%. Although this analysis can have many deficiencies, the use of images such as 
IVUS or OCT or even functional studies with iwFR or FFR can be closer to a true 
significant obstruction. It is believed that a minimum luminal diameter of 2.8 mm 
or an area of < 6 mm2 would suggest a physiologically significant obstruction [21].
2.7 Ongoing trials
Xience versus Synergy in LMCA PCI (ideal-LM), PCI of the LMCA a com-
parison of the newest generation of DES in combination with a short duration of 
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DAPT. The additional use of OCT image can be considered a standard procedure 
with a very low risk of major complications 0.4% [44]. VeRy thin Stents for 
Patients with Left mAIN or bifurcation in real life: the RAIN Multicenter Study, 
for coronary stents, reducing the thickness of the struts has become one of the 
most important innovations, since it is related to easier crushability and reduced 
risk of thrombosis and low rate of TVR. They performed a multicenter registry of 
patients treated with Biomatrix flex, Xience Alpine, Ultimaster, Resolute Onyx 
and Synergy. MACCE (death, MI, TLR and stent thrombosis) will be the primary 
end point [45].
2.8 Conclusions
In the treatment of severe LMCA in patients with low to intermediate ERACI 
score, the percutaneous treatment is of choice. In those with a higher score or 
who have total occlusions and are DM, surgical treatment is better. It is very 
important to evaluate each case in particular as well as work with a heart team to 
discuss cases that may generate controversy. The interventional cardiology must 
be trained in the different bifurcation techniques as well as have images such as 
IVUS or OCT for procedures. The implementation of the final kissing balloon and 
the POT in all patients is important. DKC seems to be the technique of choice in 
LMCA diseases with true bifurcations.
3. Patients with STEMI and MVD
3.1 Introduction
About half of the patients who enter with acute myocardial infarction with 
ST segment elevation (STEMI) have MVD [46]. Although it seems logical that 
patients with MVD have a worse prognosis, due to the extent of coronary lesions 
manifested by higher scores, this remains controversial. There are elements that 
determine that lesions at multiple sites of the coronary arteries can be compli-
cated, and there are studies in which the multivessel PCI shows a better evolution 
compared to patients in whom they only receive treatment of the culprit vessel, 
although there are other studies they don’t confirm it and consider them innocent 
[47], and therefore these arteries warrant treatment in much the same way one 
would approach any unstable lesion. An update on primary PCI for patients 
with STEMI (class IIb) [20, 48] by the guidelines recommends intervention of 
the non-culprit at the time of primary PCI if the patient is hemodynamically 
stable before the discharge. Subsequently, two randomized trials showed that 
treatment of non-culprit lesions in the acute phase reduced the risk of future 
adverse events. The PRAMI trial [49], CvlPRIT trial [50], and recently DANAMI-
3-PRIMULTI trial [51] studied the clinical outcomes by comparing the FFR 
guided by CR with culprit-only PCI in STEMI and found that the composite rate 
of all-cause mortality, nonfatal reinfarction, and repeat revascularization was 
significantly lower in the CR group, which was mainly driven by a reduction in 
repeat revascularization. More recently, another randomized trial (COMPARE 
ACUTE) [52] revealed that FFR-guided complete revascularization of non-cul-
prit arteries in an acute setting was associated with a lower risk of the composite 
cardiovascular outcome. We emphasized the importance of individualizing care 
for each patient, balancing the anticipated benefits from multivessel PCI against 
the potential risks.
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3.2 Complete vs. incomplete revascularization
Data derived from more than 150,000 patients undergoing PCI suggest that 
less than 50% of all patients with MVD have CR after they have undergone percu-
taneous revascularization. It was observed that CR is associated with a fall in the 
incidence of mortality, MI, and MACCE, regardless of whether an anatomical or 
functional definition was used for the evaluation of IR, and perhaps the degree CR 
is associated with the magnitude of the risk. The association between IR and adverse 
clinical outcomes suggests that in patients with MVD, the degree of CR that can be 
achieved by PCI should be considered when discussing the choice of revasculariza-
tion modality with the heart team, in addition to considering the complexity of the 
injury, functional significance, patient characteristics, and ERACI score [9, 53].
3.3 Randomized trials
The preventive angioplasty in acute myocardial infarction (PRAMI) study [49] 
was performed in five centers in the United Kingdom in patients with STEMI and 
MVD, where they were randomized to preventive angioplasty of non-culprit vessels 
vs. only PCI of the culprit vessel. It was the first of the trials that incorporated a new 
concept on complete revascularization in STEMI and MVD. At practically 2 years 
of follow-up, a reduction of more than 50% was observed on the primary end point 
that was the combined event of cardiac death, nonfatal MI, and refractory angina, 
of the patients of the preventive PCI group vs. PCI only of the culprit vessel. The 
study was designed to include 600 patients but was stopped early with 465 patients 
because the data was conclusive by the data security committee. CvLPRIT [50] (trial 
of primary PCI vs. complete primary injury) compared a multivessel PCI strategy 
in patients with STEMI (performed at the time of primary PCI or revascularization 
in stages before discharge) to revascularization of culprit-vessel only. In this trial, 
7 centers in the United Kingdom participated, where 296 patients were included, 
randomization was performed by stratification between previous or non-previous 
infarction, and according to the time ≤3 or >3 h. The primary end point of the study 
was the combined events of all-cause mortality, recurrent MI, heart failure, or 
revascularization driven by 12-month ischemia. The result produced a reduction of 
primary events to more than half in the CR group (10 vs. 21%; hazard ratio (HR), 
0.45; 95% CI, 0.24–0.84; p = 0.009). There were no differences in individual events. 
In the compare acute study [52] (multivessel angioplasty guided by fractional flow 
reserve in myocardial infarction), they included 885 patients in 24 centers in Asia 
and Europe, where patients with STEMI and MVD, after a primary PCI stable, were 
randomized to complete revascularization guided by FFR of the artery not culprit of 
all lesions greater than 50% vs. angioplasty only of the culprit vessel. The FFR was 
performed in both groups, but its results were blind to operators and patients in the 
culprit vessel group only. The primary end point of the study was the MACCE at 1 
year, which was significantly better in the FFR-guided group (7.8% vs. 20.5%) than 
in the culprit vessel only (HR, 0.35; 95% CI, 0.22–0.55; p < 0.001). This was at the 
expense of revascularization without changes in mortality or MI. The DANAMI-3-
PRIMULTI [51] (The Third Danish Study of Optimal Acute Treatment of Patients 
With STEMI: Primary PCI in Multivessel Disease) was conducted at two university 
centers in Denmark, where they randomized 627 patients with STEMI and MVD 
after a successful primary PCI of the culprit vessel to a complete revascularization 
guided by FFR compared to conservative treatment. The primary end point was 
MACCE, which was composed of death, nonfatal MI, and revascularization driven 
by ischemia. After an average follow-up of 27 months, it was observed that the FFR 
group presented a MACCE of 13% vs. 22% in conservative treatment (HR, 0.56; 95% 
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CI, 0.38–0.83; p = 0.004). This result was due to an excess of revascularization driven 
by ischemia in the conservative group. In the PRAGUE-13 trial [54], Ota Hlinomaz 
et al. in a university hospital in the Czech Republic randomized 214 patients with 
STEMI and MVD, who had an obstruction of at least ≥70%, to a group with CR day 
3–40 after primary PCI compared with conservative treatment, where the primary 
end point was MACCE that was composed of death from all causes, nonfatal MI, 
and stroke, and after a mean of 38 months showed no significant differences in both 
groups, (16% in CR vs. 13.9 in conservative treatment; HR, 1.35; 95% CI, 0.66–2.74; 
p = 0.407). CULPRIT-SHOCK [55] was a study that surprised in terms of results and 
gave new directives in the treatment that we had been doing in this pathology, this 
multicenter study was carried out in 83 centers in Europe that included 706 patients 
with cardiogenic shock, with SETEMI and NSTEMI, at CR compared to the treat-
ment of the culprit vessel only (CVO), whose primary end point was mortality and 
renal failure with dialysis at 30 days. The combined event occurred in 55.4 in the 
CR vs. 45.9% in the treatment of the CVO, (relative risk, 0.83; 95% CI, 0.71–0.96; 
p = 0.01). A significant difference in mortality between the two groups was also 
observed (CR 51.5 vs. CVO 43.3%; relative risk, 0.84; 95% CI, 0.72–0.98; p = 0.03).
3.4 Score to evaluate the treatment in MVD with MI
Hae Chang Jeong et al., developed a new Score to predict combined events in 
patients with AMI and MVD, the CONVERSE score, based on the PCI registry of 
nine centers in universities in Korea, in a registry of 5025 patients, evaluated 2630 
patients who AMI and MVD had presented, and they were divided into two groups 
those who were treated CVO that were 1029 patients vs. those with PCI of MVD 
1601, for this they used 8 variables that had been predictors of events in a previ-
ous study [56]. The variables were patients with arterial hypertension, diabetes, 
age over 65 years, deterioration of EF, heart failure in presentation, chronic renal 
failure, elevated CRP plasmatic, anterior descending or LMCA as culprit vessel, 
each variable awarded a point, the elevation above 3 points in these patients were in 
linear relationship with the elevation of the MACCE [57].
3.5 Meta-analysis of MVD in STEMI
In this meta-analysis of 10 trials with 2285 patients. Among the three complete 
revascularization strategies, that is, during the procedure index, during hospitaliza-
tion or after discharge vs. treatment of the culprit vessel only, it was associated with 
MACCE reduction (reference rate ratio [RR], 0.57; 95% CI, 0.42–0.77), due to a lower 
rate of emergency revascularization. Mortality of all causes and spontaneous rein-
farction was similar between the two groups. There were no differences between the 
different types of strategies at the time of revascularization in patients with CR [58].
3.6 An algorithm for the management of STEMI patients with MVD
Figure 2 [59].
3.7 Guidelines
MVD PCI treatment during STEMI is considered strongly indicated when there 
are critical lesions or associated thrombotic lesions when the culprit vessel has 
already been treated if there is persistent ischemia. When there is cardiogenic shock, 
the only treatment of the culprit vessel is the treatment of choice [20]. Patients with 
stable STEMI and MVD after a primary PCI the recommendation of multivessel PCI 
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has been updated to a Class IIB, this could be done at the time of the primary index 
or in stages during hospitalization or after discharge [48].
3.8 Ongoing trials
The COMPLETE [60] (Complete vs. Culprit-only Revascularization to Treat 
Multi-vessel Disease After Primary PCI for STEMI) trial will compare the outcomes 
of approximately 3900 patients randomized to a strategy of staged multivessel PCI or 
culprit-only revascularization. The FULL REVASC [61] (FFR-Guidance for Complete 
Non-Culprit Revascularization) This trial intends to evaluate the CR in about 4000 
patients with STEMI or not with very high risk in patients of MVD guided by FFR 
during the same hospitalization of the index procedure, to evaluate clinical results.
3.9 Our experience
We were the precursors in the treatment of primary PCI in acute infarction as 
revealed by one of the first randomized trials with stent in acute myocardial infarc-
tion, our trial GRAMI [62]. In our daily practice we try to identify culprit vessel. If 
we have a territory where we find two vessels with critical lesions, we treat them. 
If the patient presents a critical lesion in another territory, we defer to perform it 
pre-discharge. We also consider the amount of territory that this vessel irrigates as 
well as its renal function when making the decision with the heart team.
3.10 Conclusions
Multivessel PCI both during the index procedure and in stages in stable patients is 
safe and could lead to better long-term results at the expense of reducing emergency 
Figure 2. 
Algorithm for the Management of STEMI Patients With MVD. Modified from “The Management of MVD in 
STEMI: The Science and Art of Decision-Making in STEMI” (Feb 07, 2018) (Jacqueline E. Tamis-Holland, 
MD, FACC; Addi Suleiman, MBBS).
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revascularization without altering mortality. The PCI of associated intermediate or 
very complex lesions at the time of STEMI is contraindicated. In cardiogenic shock 
and MVD, the treatment of the culprit vessel is only the indication. When one faces 
a patient with STEMI and MVD, the analysis of a heart team, where the scores are 
analyzed, the clinical status, the comorbidities, as well as the common sense should 
define the opportunity of the treatment of the non-culprit critical lesions.
4. Diabetes and multivessel disease
4.1 Introduction
DM is a global health problem; about 10% of adult patients will have the disease, 
and a quarter of all revascularized patients globally have DM [63]. However, patients 
with DM compared to nondiabetics have more MACCE and chronic heart failure. 
In addition, these patients have diffused and segmental disease, which puts them 
at greater risk of events regardless of the revascularization selected [64, 65]. PCI 
is limited by a higher rate of repeat revascularization and a worse clinical outcome 
in DM patients than with nondiabetic patients. CABG carries a greater morbidity, 
increased length of stay, and longer recovery times. However, both strategies have 
been improved during the last decade. In particular, the introduction of DES [66] 
has dramatically changed the landscape for PCI, with a significant reduction in the 
rate of restenosis especially the so-called second-generation stents that can reduce 
the gap [67]. The FREEDOM trial [68] demonstrated lower rates of major adverse 
cardiovascular events in patients with stable ischemic coronary disease who were 
assigned to CABG than with PCI using DES of first generation, at long-term follow-
up. It is evident that this pathology carries a high atherogenic risk, and its current 
treatment is of surgical competence. Even so, we think that patients with a low 
ERACI score [17] are good candidates for PCI treatment, and the arrival of the new 
generation stents of Ultrathin-Strut DES [69] could reduce the gap that was created.
4.2 FREEDOM, critics, and main trials
This trial [68] has become the most important among patients with diabetes and 
type of revascularization as well as follow-up, which was carried out worldwide in 
140 centers that included 1900 patients with DM with MVD who were random-
ized to PCI with DES from first generation or CABG and its long-term follow-up 
of at least 5 years. The primary end point was the combined mortality events of all 
causes, nonfatal MI, and stroke, such as MACCE. The MACCE was significantly in 
favor of the CABG (18.7% vs. 26.6%, p < 0.005), there was also a decrease in the 
mortality of all causes (10.9% vs. 16.9%, p = 0.049), the stroke was lower in the PCI 
group (2.4% vs. 5.2%, p = 0.03), and the revascularization of the treated vessel was 
highly significant in favor of the CABG almost three more times on the first year 
of follow-up. The nonfatal MI was almost double with the PCI group [68]. When 
the quality of life was evaluated, it was although slightly significantly better with 
surgery than with PCI; this is due to the amount of repeated revascularization. So, 
this study showed strong data and full impact on revascularization guidelines [70]. 
Also with respect to FREEDOM, a study of hospital costs was carried out; it was 
also favorable for surgical treatment vs. percutaneous treatment [71].
The study showed that the outcomes were significantly lower among patients 
randomized to CABG (18.7%) than patients randomized to PCI (26.6%) 
(Figure 3A). A closer look at how these rates were derived is warranted. A total 
of 1900 patients (953 in the PCI group and 947 in the CABG group) were enrolled 
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and randomized. However, for the 5-year outcome rates, the denominator was 752 
for PCI and 781 for CABG. These numbers are not the group totals but rather the 
number of patients remaining at risk at the end of the study. The number of events 
and the number remaining at risk are independent of each other. A basic occupant 
of a rate is that the subjects in the numerator are included in the denominator. The 
percentages the authors report are not rates; they are ratios and are very mislead-
ing. Calculating the events among the number randomized in each group results in 
a relative difference of 26% that is less significant than reported (Figure 3B). We 
would have more confidence in these recalculated rates if the study included all 
subjects in the denominator and accounted for outcomes on all subjects. They do 
not include the 214 (11.3%) patients lost to follow-up for whom we have no outcome 
data. This study also experienced a significant differential in attrition by group. The 
CABG group had twice the patients lost to follow-up (14.9%) as the PCI group did 
(7.7%). Revising the comparison by adding in the lost patients as events and calcu-
lating it with an intention-to-treat analysis (attributing events to the group of origi-
nal assignment), we get a very different picture for the 5-year outcome (Figure 3C). 
The relative 5% difference is not significant (p = 0.42). This finding is in line with 
the 2-year composite outcomes in which the study authors observed no difference 
in outcome rates (13.0% vs. 11.9%, p = 0.51). The 5-year finding is significantly 
biased by the differential FREEDOM trial results comparing ITT analyses [72]. 
Other points of FREEDOM, which used first-generation stents that are currently 
discontinued, we remember presented a high rate of thrombosis stent [73]. Also in 
the trial a great geographical disparity was observed, since this difference marked 
by the study only was able to observe in the United States and the other centers 
in the randomization, and there were no significant differences outside of North 
American centers [68]. VA CARDS trial [74] is a study of veteran hospitals in the 
USA, in 22 centers, and included diabetic patients with MVD and 198 patients to be 
revascularized to PCI with DES or CABG with a 2-year follow-up. The primary end 
point of the study was the combined death events of all causes and nonfatal MI. The 
study was stopped early due to very slow recruitment by enrolling a quarter of the 
pre-established patients, which did not produce the power necessary for the evalu-
ation of events. Within the study, it was observed that mortality in the 2-year PCI 
group reached a very high number up to 21% vs. 5% for CABG, while mortality was 
very high in the CABG group up to 15% compared with 6.2% for the PCI. This study 
Figure 3. 
A.B.C. FREEDOM trial results comparing ITT analyses. CABG, coronary arterial bypass graft surgery; ITT, 
intention-to-treat analysis; PCI, percutaneous coronary intervention. From “Critical appraisal of cardiology 
guidelines on revascularization: clinical practice” (David R Dobies and Kimberly R Barber).
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was inconclusive. CARDia trial was a randomized study conducted in 22 centers in 
the United Kingdom and 2 centers in Ireland. Where Diabetic patients with MVD 
and patients with complex single lesion defined as ostial or proximal lesion of the 
anterior descending artery, which did not include LMCA between PCI or CABG, 
BMS was initially used, but when available the DES were used with the Axicimab 
adjuvant. A total of 510 patients were included, in which the primary end point 
was the MACCE, which included death of all causes, MI, and stroke. The study was 
non-inferior and with a 1-year follow-up. After 1 year the MACCE was 10.5% in the 
CABG group and 13% in the PCI group (HR, 1.25; 95% CI, 0.75–2.09; p = 0.39); the 
mortality of all the causes were the same in both groups of 3.2% (HR, 0.98; 95% CI, 
0.37–2.6; p = 0.97). Although the study did not reach non-inferiority, it made the 
PCI as feasible [75].
4.3 Meta-analysis of MVD and DM
In this meta-analysis of the individual database of patients, where they analyzed 
11 trials of patients with MVD followed in the long term, who were randomized to 
PCI or CABG, in the subgroup of patients with DM, it was observed that mortality 
was significantly higher in patients with PCI 15.7% than with CABG, which was 
10.7% (p = 0.0001), while no differences were found among non-DM patients, 
8.4% for CABG and 8.7% in the PCI group (p = 0.81) [43].
4.4 Our experience
In the ERACI III registry [76] which included 3 cohorts of 225 patients in each 
group with multiple MVD and PCI with DES, PCI with BMS, and patients with 
CABG, we analyzed the results of the subgroup of diabetic patients in each group 
at 3 years of follow-up. The incidence of MACCE at 3 years was significantly higher 
in diabetics than nondiabetics (RR, 0.81 [0.66–0.99]; p = 0.018). Higher rates of 
death and nonfatal AMI and a trend toward increased TVR, among others, were the 
principal determinants of increased MACCE. When stratified by treatment modal-
ity, MACCE rates among diabetics at 3 years were 36.2% in the DES arm, 43.6% in 
the BMS arm, and 30.8% in the CABG group (p = 0.49). There was a nonsignificant 
trend toward more death and nonfatal MI among diabetics in the ERACI III-DES 
cohort (19.1%) than in the BMS (12.8%) or CABG (15.4%) arms of ERACI II. Just 
as in the FREEDOM trial, the only stents used were the first-generation stents. 
Another limitation is that it was not a randomized trial, but they were two well-
followed cohorts.
4.5 Can newer generation DES bridge the gap?
A total of 69 randomized trials that enrolled 24,015 diabetic patients with a total 
of 71,595 patient-years of follow-up satisfied our inclusion criteria. When compared 
with CABG (RR = 1.0), PCI with paclitaxel-eluting stent (RR = 1.57 [1.15–2.19]) 
or sirolimus-eluting stent (RR = 1.43 [1.06–1.97]) was associated with an increase 
in mortality. However, PCI with EES (RR = 1.11 [0.67–1.84]) was not associated 
with a statistically significant increase in mortality. In PCI with EES (RR = 1.31 
[0.74–2.29]), the excess repeat revascularization was not statistically significant 
although the point estimate favored CABG. CABG was associated with numeri-
cally higher stroke. In patients with DM, evidence from indirect comparison shows 
similar mortality between CABG and PCI using EES. CABG was associated with 
numerically excess stroke and PCI with EES with numerically increased repeat 
revascularization [67].
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4.6 Guidelines
Overall current evidence continues to favor CABG as the revascularization 
modality of choice for patients with diabetes and multivessel disease. When 
patients present with a comorbidity that increases surgical risk, the choice of 
revascularization method is best decided by multidisciplinary individualized risk 
assessment [20].
4.7 Conclusions
In this group of patients at high risk of diffuse coronary disease, there is evi-
dence that patients with high scores are no doubt that surgery is the first option, 
although the only definitive evidence is FREEDOM despite its criticisms. Since 
the other studies could not be completed or did not show long-term follow-up, in 
patients with low scores, we believe that second-generation stents and perhaps 
new ultra-thin DES stents could shorten the gap between surgery events and 
angioplasty.
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